Motif Bio PLC New Addition to Scientific Advisory Board
15 Luglio 2015 - 8:00AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
15 July 2015
15 July 2015
Motif Bio plc
("Motif" or the "Company")
Motif Bio Appoints Dr. Thomas M. File to its Scientific Advisory
Board
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, today
announced the appointment of Dr. Thomas M. File to its Scientific
Advisory Board. Currently, Dr. File, a renowned expert in
infectious diseases, Chairs the Division of Infectious Diseases at
Summa Health System, Akron, Ohio, is Professor of Internal Medicine
and Master Teacher, and the Chair of the Infectious Disease Section
of Northeast Ohio Medical University (NEOMED).
Dr. File is a highly respected and internationally recognized
expert on infectious diseases including skin and skin structure
infections (SSSIs) and pneumonia. Previously, Dr. File served as
Past-President and as a member of the Board of Directors for the
National Foundation for Infectious Diseases and on the Board of
Directors for the Infectious Disease Society of America. In 2010,
he was elected as a Faculty Member to the Alpha Omega Alpha
Honorary Society and in 2013, was recipient of the Watanakunakorn
Clinician Award of the Infectious Diseases Society of America.
Over the last 38 years, Dr. File has published over 275 original
papers and numerous review articles and delivered some 145
presentations on various aspects of infectious diseases at
scientific meetings throughout the USA and internationally. He
currently, serves on the Editorial Boards of Infectious Diseases in
Clinical Practice, where he is Editor-in-Chief; Infectious Disease
News; plus the Journal of Microbiology and Immunology and
Infection.
Dr. David Huang, Chief Medical Officer at Motif Bio plc,
commented: "We are very pleased to welcome Dr. Tom File to our team
of scientific experts. Dr. File's extensive clinical and research
knowledge in infectious diseases, especially in the management and
treatment of SSSIs and pneumonia, will provide critical expert
input into the clinical development of our anti-bacterial
programmes for serious and life threatening conditions."
Enquiries
For further information please contact
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
Robert Bertoldi (Chief Financial
Officer)
www.motifbio.com
Zeus Capital Limited (Nominated +44 (0) 207
Advisor and Broker) 533 7727
Phil Walker / John Treacey
Dominic Wilson
Northland Capital Partners Limited +44 (0) 20
(Broker) 7382 1100
Gerry Beaney/David Hignell
John Howes/Mark Treharne (Broking)
Plumtree Capital Limited (Financial
Advisor) +44 (0) 207
Stephen Austin 183 2493
+49 (0) 89
MC Services AG (Public Relations) 210 2280
Raimund Gabriel +44 (0) 207
Shaun Brown 148 5998
Yellow Jersey PR Limited (Investor
Relations)
Dominic Barretto +44 (0) 7768
Fiona Walker 537 739
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which
specialises in developing novel antibiotics designed to be
effective against serious and life-threatening infections caused by
multi-drug resistant bacteria. The Company has a lead antibiotic
candidate, iclaprim, in clinical development and MTF-001, a
preclinical stage programme to design a best-in-class dihydrofolate
reductase inhibitor (DHFRi).
Iclaprim is being developed for the treatment of the most common
and serious bacterial infections such as acute bacterial skin and
skin structure infections (ABSSSI) and hospital acquired bacterial
pneumonia (HABP), including those caused by resistant strains such
as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP
(multi-drug resistant Streptococcus pneumoniae) that have become
prevalent in patients in both the community and hospital
settings.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFVEDTISLIE
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024
